[go: up one dir, main page]

DK0946199T3 - TGF betal 1-responsive celler fra knoglemarv - Google Patents

TGF betal 1-responsive celler fra knoglemarv

Info

Publication number
DK0946199T3
DK0946199T3 DK97947454T DK97947454T DK0946199T3 DK 0946199 T3 DK0946199 T3 DK 0946199T3 DK 97947454 T DK97947454 T DK 97947454T DK 97947454 T DK97947454 T DK 97947454T DK 0946199 T3 DK0946199 T3 DK 0946199T3
Authority
DK
Denmark
Prior art keywords
bone marrow
cells
tgf
pays
marrow cells
Prior art date
Application number
DK97947454T
Other languages
English (en)
Inventor
Erlinda Maria Gordon
Frederick L Hall
W French Anderson
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of DK0946199T3 publication Critical patent/DK0946199T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK97947454T 1996-11-12 1997-11-12 TGF betal 1-responsive celler fra knoglemarv DK0946199T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/747,514 US6063593A (en) 1996-11-12 1996-11-12 TGFβ1 responsive bone marrow derived cells to express a recombinant protein
PCT/US1997/020558 WO1998020907A1 (en) 1996-11-12 1997-11-12 TGFβ1-RESPONSIVE CELLS FROM BONE MARROW

Publications (1)

Publication Number Publication Date
DK0946199T3 true DK0946199T3 (da) 2008-08-25

Family

ID=25005386

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97947454T DK0946199T3 (da) 1996-11-12 1997-11-12 TGF betal 1-responsive celler fra knoglemarv

Country Status (12)

Country Link
US (4) US6063593A (da)
EP (1) EP0946199B1 (da)
JP (2) JP2001503989A (da)
AT (1) ATE397461T1 (da)
AU (1) AU5253498A (da)
CA (1) CA2271734A1 (da)
DE (1) DE69738753D1 (da)
DK (1) DK0946199T3 (da)
ES (1) ES2308790T3 (da)
NZ (1) NZ335753A (da)
PT (1) PT946199E (da)
WO (1) WO1998020907A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
AU759643B2 (en) * 1999-07-20 2003-04-17 University Of Southern California Identification of pluripotent pre-mesenchymal, pre-hematopoietic progenitor cell
JP2003018984A (ja) * 2001-07-06 2003-01-21 Mitsubishi Chemicals Corp 多分化能を有する細胞の製造法
WO2003051283A2 (en) * 2001-10-26 2003-06-26 The Children's Hospital Of Philadelphia Engineered bone marrow
JP2005531507A (ja) * 2002-03-02 2005-10-20 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ストローマ細胞前駆体による抗癌物質の局所的な産生および／または送達方法
AU2003233428B2 (en) * 2002-04-01 2008-07-31 The University Of Texas Medical Branch Treatment of lung disorder
US20040052771A1 (en) * 2002-07-12 2004-03-18 Lim Sai Kiang Hemangioblast progenitor cells
AU2003248609A1 (en) * 2002-07-12 2004-02-02 Agency For Science, Technology And Research Hemangioblast progenitor cells
US20040091503A1 (en) * 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
US8147806B2 (en) 2004-01-16 2012-04-03 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
JP2006249072A (ja) * 2005-02-09 2006-09-21 Osaka Univ タンパク質導入用担体、前記担体を用いたタンパク質導入剤、タンパク質導入方法、およびタンパク質導入細胞ならびにその製造方法
EP3712258B1 (en) 2006-04-14 2025-01-01 Astellas Institute for Regenerative Medicine Hemangio-colony forming cells
JP2009533684A (ja) 2006-04-14 2009-09-17 カーネギー・メロン・ユニバーシティ 核磁気共鳴技術のための細胞標識及び定量
AU2008275578B2 (en) 2007-07-10 2014-04-10 Carnegie Mellon University Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques
CN112280739A (zh) 2008-05-06 2021-01-29 安斯泰来再生医药协会 用于制备衍生自多能干细胞的去核类红细胞的方法
EP3441462A1 (en) 2008-05-06 2019-02-13 Astellas Institute for Regenerative Medicine Hemangio colony forming cells and non-engrafting hemangio cells
US8583299B2 (en) * 2009-03-17 2013-11-12 General Electric Company System and method for communicating data in a train having one or more locomotive consists
MX2012005527A (es) 2009-11-13 2012-08-08 Grifols Therapeutics Inc Preparaciones que contienen el factor de von willebrand (fvw) procedimientos, kits y aplicaciones relacionados con las mismas.
US10420820B2 (en) * 2014-09-29 2019-09-24 Counterpoint Biomedia LLC Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptides
US11406721B2 (en) 2016-02-22 2022-08-09 The Regents Of The University Of California Compositions and methods for imaging cell populations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein

Also Published As

Publication number Publication date
EP0946199A4 (en) 2002-11-27
JP4767983B2 (ja) 2011-09-07
EP0946199B1 (en) 2008-06-04
US20020141982A1 (en) 2002-10-03
ATE397461T1 (de) 2008-06-15
PT946199E (pt) 2008-09-01
JP2001503989A (ja) 2001-03-27
ES2308790T3 (es) 2008-12-01
US6277369B1 (en) 2001-08-21
US6063593A (en) 2000-05-16
US6410015B1 (en) 2002-06-25
EP0946199A1 (en) 1999-10-06
CA2271734A1 (en) 1998-05-22
US6844191B2 (en) 2005-01-18
DE69738753D1 (de) 2008-07-17
NZ335753A (en) 2001-02-23
JP2008206520A (ja) 2008-09-11
AU5253498A (en) 1998-06-03
WO1998020907A1 (en) 1998-05-22

Similar Documents

Publication Publication Date Title
DK0946199T3 (da) TGF betal 1-responsive celler fra knoglemarv
AU8476698A (en) Human mesenchymal stem cells from peripheral blood
He et al. Sox9 positive periosteal cells in fracture repair of the adult mammalian long bone
TW428026B (en) Bifunctional protein, preparation and use
AU7297298A (en) Apparatus and methods for anchoring autologous or artificial tendon grafts in bone
EP0765386A4 (en) METHODS FOR ACTIVATION OF IN VIVO T CELLS BY ANTIGENIC PULSE DENDRITIC CELLS
ATE213271T1 (de) Verfahren zur herstellung von rekombinanten proteinen in e. coli mittels hochzelldichte- fermentation
DE69733605D1 (de) In vivo gentransfermethoden zur wundheilung
NZ334546A (en) Erythropoietin receptor agonist and use in the treatment of hematopoietic disorders
ATE313634T1 (de) Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose
NZ331517A (en) A method for making and/or repairing cartilage in vivo by implanting a scaffold or framework in combination with periosteal/perichondrial tissue that holds the scaffold in place
GR1002147B (en) Human tissue factor related dna segments poypeptides and antibodies
EP0987998A4 (en) DECELLULARIZATION OF A FABRIC
ES8704546A1 (es) Metodo de produccion de una proteina con actividad procoagu-lante del tipo de factor viii:c humano
ATE350474T1 (de) Bpc-1: ein ausgeschiedenes gehirnspezifisches protein das von prostata- und blasen-krebszellen exprimiert und ausgeschieden wird
EP1014880A4 (en) INCREASE OR REPAIR OF SKIN TISSUE, SUBCUTANEOUS OR VOICE ROPE ABNORMALITIES
BR9708049A (pt) Processo para matar células alvo indesejadas em uma população de células imunotoxinas para matar células uso das mesmas e kit para realizar o processo
DE68913991D1 (de) Implantat zur verwendung in der knochenchirurgie.
GR3031229T3 (en) Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease
DE69734464D1 (de) Verfahren zur expression und herstellung von rekombinantem, menschlichem beta-cis-interferon
DK0928294T3 (da) Fremgangsmåde og apparat til fremstilling af en acellulær rød blodlegeme-erstatning
DE50312433D1 (de) Gezüchtete knorpelzellen beinhaltendes implantat und verfahren zur herstellung
PT1007559E (pt) Celulas geneticamente modificadas que expressam as proteinas morfogeneticas do osso
WO2002050111A3 (en) Isolated laminin 10
AU4037299A (en) Genetically-modified fibroblasts and the use thereof